News

November 26, 2019November 26, 2019

FDA Approves Calquence as Treatment Option for Adults with CLL and SLL

News

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was ... Read more

November 22, 2019November 22, 2019

EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL

News

An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment ... Read more

November 19, 2019November 19, 2019

FDA Approves BeiGene’s Brukinsa to Treat Adults with Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at ... Read more

November 15, 2019

Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection

News

The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory ... Read more

November 14, 2019December 20, 2019

FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell ... Read more

November 12, 2019

Janssen Requests FDA Approval of Imbruvica-rituximab Combo for First-line Treatment of CLL/SLL

News

Janssen is seeking approval from the U.S. Food and Drug Administration (FDA) for a combination of Imbruvica (ibrutinib) with rituximab to be used as a first-line treatment for people ... Read more

November 8, 2019

Advanced Follicular Lymphoma Patients Show Positive Overall Response to Umbralisib in Phase 2 Trial

News

TG Therapeutics’ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising response rates in patients with relapsed or refractory follicular lymphoma, according to new data from a ... Read more

November 7, 2019November 7, 2019

First Patient Enrolled in Trial Testing Defitelio to Prevent Neurotoxicity in DLBCL Patients Receiving CAR T-cell Therapy

News

Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory ... Read more

November 5, 2019

Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and ... Read more

November 1, 2019November 11, 2019

Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show

News

Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 ... Read more

Pin It on Pinterest